Breakdown | |||||
TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.10M | 18.63K | 147.81K | 349.94K | 483.63K | 0.00 | Gross Profit |
-3.48M | 18.63K | -11.67M | 256.69K | -16.15M | -58.31K | EBIT |
-13.42M | -11.85M | -18.79M | -29.67M | -25.09M | -24.24M | EBITDA |
-13.38M | -11.85M | -18.72M | -29.58M | -24.99M | -24.24M | Net Income Common Stockholders |
-9.43M | -7.44M | -18.83M | -29.77M | -25.01M | -31.06M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
4.86M | 149.46K | 2.27M | 3.05M | 27.62M | 7.35M | Total Assets |
7.18M | 2.77M | 5.43M | 5.83M | 28.99M | 7.99M | Total Debt |
110.96K | 130.86K | 203.91K | 255.99K | 125.88K | 353.25K | Net Debt |
-4.75M | -18.59K | -2.07M | -2.80M | -27.50M | -7.00M | Total Liabilities |
3.15M | 3.26M | 5.66M | 8.37M | 6.73M | 4.97M | Stockholders Equity |
4.04M | -485.74K | -225.98K | -2.54M | 22.26M | 3.02M |
Cash Flow | Free Cash Flow | ||||
-8.44M | -8.61M | -21.79M | -28.58M | -22.56M | -15.69M | Operating Cash Flow |
-8.43M | -8.61M | -21.34M | -27.69M | -22.55M | -15.61M | Investing Cash Flow |
-12.00K | -12.00K | -443.25K | -896.48K | -3.62K | -76.18K | Financing Cash Flow |
10.28M | 6.49M | 21.01M | 4.01M | 42.83M | 23.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
43 Neutral | $14.41M | ― | -474.63% | ― | ― | 50.73% | |
38 Underperform | $4.26M | ― | -285.35% | ― | 674.14% | 89.05% | |
37 Underperform | $166.31M | ― | 123.38% | ― | -42.30% | -9.33% | |
36 Underperform | $3.52M | ― | -807.39% | ― | -80.98% | 62.27% | |
36 Underperform | $3.29K | ― | -192.88% | ― | -49.41% | 78.46% |
On February 26, 2025, Sonnet BioTherapeutics announced the presentation of data at the 2025 AACR IO Conference, highlighting the potential of their drug SON-1010 for treating solid tumors. The presentation showcased the company’s FHAB platform, which improves drug targeting and retention in tumors, potentially enhancing therapeutic outcomes. The data included ongoing trials of SON-1010 as a monotherapy and in combination with other treatments, showing promising results in patients with advanced solid tumors. These developments could significantly impact Sonnet’s positioning in the oncology field by addressing unmet needs and improving patient outcomes.
On February 19, 2025, Sonnet BioTherapeutics announced advancements in its proprietary Antibody Drug Conjugate (ADC) platform, designed to address technical challenges in ADC development. The platform, now available for drug discovery partnerships, aims to produce multiple drug candidates. The initial proof-of-concept, SON-5010, demonstrated similar activity to existing treatments in preclinical studies, indicating potential for novel ADCs with flexible payloads and tumor targeting capabilities.
On January 28, 2025, Sonnet BioTherapeutics announced that the European Patent Office granted a patent for its FHAB technology, which includes therapeutic fusion proteins for tumor targeting and extended pharmacokinetics. This EU patent, effective until 2038, significantly expands Sonnet’s global intellectual property portfolio, which now includes coverage in China, Japan, Russia, and New Zealand. The patent strengthens Sonnet’s market position by providing expanded global protection and differentiation from competitors. This development is seen as a milestone that validates the company’s FHAB platform, enhancing its competitive edge in the biotechnology industry.
On January 21, 2025, Sonnet BioTherapeutics announced the expansion of its Phase 1 SB101 clinical study to evaluate SON-1010 in combination with trabectedin in adult patients with advanced solid tumors, specifically targeting soft-tissue sarcomas. The expansion follows successful monotherapy dose escalation and aims to explore immune-oncology impacts at a maximum tolerated dose. The new cohort will assess the potential for enhanced progression-free survival and improved therapeutic outcomes for soft-tissue sarcoma patients. Enrollment is underway with results expected in late 2025, potentially positioning SON-1010 for a Phase 2 study and establishing a new treatment option for soft-tissue sarcoma.